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Management of preeclampsia and eclampsia
JACK A. PRITCHARD
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School, Dallas, Texas
In some mysterious way, the presence of cho-
rionic villi in certain women incites vasospasm and
hypertension. Moreover, to effect a cure, the cho-
rionic villi must be expelled or surgically removed.
The vasospastic hypertensive state and related
pathologic changes that are somehow induced by
the presence of chorionic villi may not become so
intense that pregnancy need be terminated pre-
maturely. Instead, under close observation, the
mother and fetus can continue to coexist with bene-
fit to the fetus and little risk of immediate or remote
harm to the mother. There are times, however,
when the functional derangements induced by the
vasospastic process are so severe and unremitting
that not only is termination of the pregnancy essen-
tial to the welfare of the mother but the intrauterine
environment becomes intolerably hostile to the fe-
tus.
Preeclampsia and eclampsia develop most often
in the first pregnancy. These conditions may also
occur in later pregnancies, but in such instances
there is almost always a predisposing factor such as
diabetes, multiple fetuses, fetal hydrops, hydatidi-
form mole, or underlying chronic vascular disease.
The syndrome of preeclampsia-eclampsia is unique
to pregnant and puerperal women; it neither occurs
spontaneously nor has it been experimentally pro-
duced in animals.
Definitions. When the etiology of a disease or
syndrome is not known precisely, the terminology
used is likely to prove confusing. Unfortunately,
this has been a persistent problem with hyperten-
sive disorders complicating pregnancy. For ex-
ample, some previously recommended terminology
was so lax that hypertension was not a requirement
for the diagnosis of preeclampsia [1]. Moreover, pa-
thologists, at times, have made the diagnosis of
eclampsia solely on the basis of autopsy findings
even though the woman demonstrated none of the
clinical features of the disease before death. To try
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to minimize confusion, I have defined the terms
used in this report as follows:
The development of hypertension during preg-
nancy, but not as the consequence of a coincidental
disease, is categorized as pregnancy-induced hyper-
tension. Intensification of hypertension in women
whose blood pressure was elevated before the preg-
nancy is referred to as pregnancy-aggravated hy-
pertension. Often, but not always, generalized ede-
ma, proteinuria, or both, either coexist with hyper-
tension induced or aggravated by pregnancy, or
they may develop subsequently. When hyper-
tension with proteinuria, overt edema, or both,
arises de novo in pregnancy, the condition is called
preeclanipsia; when preexisting hypertension is in-
tensified by pregnancy and is accompanied by pro-
teinuria, overt edema, or both, the condition is re-
ferred to as superimposed preeclampsia. If the
pregnancy-induced or pregnancy-aggravated hyper-
tensive disorder causes convulsions, the condition
is called eclainpsia. Preeclampsia or eclampsia
rarely develops before 24 weeks of gestation unless
there is either a hydatidiform mole or, at least, ex-
tensive molar change in the placenta.
'Toxemia of pregnancy" and "toxemias of preg-
nancy" are catch-all terms that have served only to
promote confusion and will not be used.
Severity of disease
Eclampsia, unless expertly managed, can kill the
mother and fetus. Satisfactory treatment of eclamp-
sia requires termination of the pregnancy with rare
exception; the same holds true for severe pre-
eclampsia.
Received for publication January 7, 1980
0085—2538180/0018-0259 $01.60
© 1980 by the international Society of Nephrology
260
Severe preeclampsia is characterized by one or
more of the following features: (1) blood pressures
of 160 mm Hg or more systolic, or 110 mm Hg or
more diastolic, that persist with the woman at bed
rest, (2) proteinuria of 5 g or more in 24 hours (3 or 4
plus on qualitative examination), (3) oliguria (500 ml
or less in 24 hours), (4) overtly elevated plasma
creatinine (decreased creatinine clearance), (5) un-
remitting cerebral or visual disturbances, (6) per-
sistent epigastric or right upper quadrant pain, (7)
thrombocytopenia, (8) hemogiobinemia-hemoglo-
binuria, (9) hyperbilirubinemia, (10) pulmonary ede-
ma or cyanosis. Abnormalities seven through ten
are least often seen, but are ominous.
The differentiation between severe and mild pre-
eclampsia is not wholly desirable, except in retro-
spect, because an apparently mild case can rapidly
become severe. Unfortunately, the reverse is not
true; a severe case rarely, if ever, becomes mild.
The basic objectives of management of any preg-
nancy complicated by preeclampsia or eclampsia
are (1) termination of the pregnancy with the least
amount of trauma to the mother and fetus; (2) birth
of an infant who subsequently thrives; and (3) com-
plete restoration of the mother's health. A great va-
riety of treatment regimens have been applied to try
to accomplish these goals. Unfortunately, all treat-
ment regimens are empiric. Moreover, the efficacy
of only a few has been supported by sufficient data
obtained through appropriate clinical trials.
At the University of Texas Southwestern Medical
School and Parkiand Memorial Hospital members
of the Department of Obstetrics and Gynecology
have evaluated over many years a specific, albeit
empiric, regimen for the treatment of pregnancies
complicated by eclampsia or severe preeclampsia,
as well as one for pregnancies in which pre-
eclampsia was mild to moderate.
Treatment of eclampsia and severe preeclampsia
In 1955, a protocol for the treatment of eclampsia
was established, which has been adhered to since
its inception. The results of 20 years' experience
with this regimen have been published [2]. With this
simple treatment, all of the mothers survived. All
infants also survived, except for those who were
dead when the mother was first seen with eclampsia
or were quite premature. No infant who weighed
1800 g (4 pounds) or more succumbed. An outline of
the treatment regimen is presented: (1) Magnesium
sulfate was administered parenterally to arrest the
convulsions of eclampsia (and to prevent con-
vulsions in case of severe preeclampsia). (2) Hy-
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dralazine was administered parenterally to lower
blood pressure whenever the diastolic blood pres-
sure was 110 mm Hg or more. (3) Steps were taken
to effect delivery once the woman was conscious.
Neither diuretics nor hyperosmotic agents were
administered. Heparin was never used even when
thrombocytopenia or other laboratory evidence was
found that might be construed to be indicative of
disseminated intravascular coagulation. Spinal and
epidural anesthesia was avoided because hypoten-
sion might have developed as the consequence of
sympathetic blockade and thereby jeopardized pla-
cental perfusion.
Arrest and prevention of convulsions with mag-
nesium sulfate: (A) Dosage. As soon as eclampsia
was considered the likely diagnosis, magnesium sul-
fate (MgSO47 H20, USP) was administered as fol-
lows: A 20-mi injection of 20% magnesium sulfate
solution (4 g) was given i.v. at the rate of I g/min.
This was immediately followed by 20 ml of 50%
magnesium sulfate solution, one half (5 g) injected
deeply into the upper outer quadrant of each but-
tock through a 3-inch-long, 20-gauge needle. Every
4 hours thereafter, 10 ml of 50% magnesium sulfate
solution (5 g) was similarly injected i.m. into alter-
nate buttocks but only after it was ascertained that
(1) the knee jerk (patellar reflex) was present, (2)
urine flow was 100 ml or more in the previous 4
hours, and (3) respirations were not depressed.
Magnesium sulfate so administered nearly always
promptly arrested the convulsions. If, however, an-
other convulsion did develop and the i.v. and the
i.m. injections of magnesium sulfate were com-
pleted no more than 20 mm before, the subsequent
convulsion usually was brief and did not recur. In
the very unusual circumstance in which the interval
was much longer than 20 mm or if convulsions re-
curred, the i.v. dose of 4 g was repeated, unless the
woman was small, when 2 g were injected i.v. In the
rare case in which convulsions persisted, sodium
amobarbital, up to 0.25 g, was slowly injected in in-
crements i.v. over a period of not less than 3 mm.
Data from a case of eclampsia treated initially with
a total of 8 g of magnesium sulfate i.v., rather than 4
g, are presented in Fig. 1.
(B) Absorption, distribution, and excretion. Given
i.v. over 4 mm, 4 g of magnesium sulfate increases
the plasma concentration to about 7 to 9 mEq/liter.
The level falls to about 4 to 5 mEq/liter over the
next 45 mm. Immediately following the i.v. dose,
the injection of 10 g of magnesium sulfate, i.m.,
one-half in the upper outer quadrant of each but-
tock, and followed by 5 g every 4 hours i.m. in alter-
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Fig. 1. Antepartum eclampsia in a 15-year-old primigravid woman treated with magnesium sulfate. She was atypical in that she con-
vulsed again shortly after having received the i.v. loading dose of 4 g and i.m. dose of lOg of magnesium sulfate. Over 5 mm she received
4 g or more of magnesium sulfate in a 20% solution i.v. and suffered no more convulsions. She then awoke, and her sensorium soon
cleared. The patellar reflex was absent when the plasma magnesium level was 9.9 mEq/liter very soon after the initial injections but
returned to activities described as "2 plus" to "4 plus" with plasma magnesium concentrations of 6.5 mEq/liter. The clearance of
magnesium by the kidney approached that of the creatinine clearance, which was reduced until after delivery. The magnesium concentra-
tions in maternal and cord plasma were the same.
nate buttocks, typically stabilizes the plasma mag-
nesium level at about 4 to 7 mEq/liter [3, 4].
Others have reported the successful use of mag-
nesium sulfate, administering 5 g i.v. as a loading
dose, followed by 1 to 2 g/hour by continuous i.v.
infusion [5]. The i.m. route for maintenance therapy
is preferred at Parkland Memorial Hospital for sev-
eral reasons set forth elsewhere [6].
The parenterally injected magnesium ion rapidly
distributes in the extracellular fluid of the mother
and rapidly crosses the placenta. Its route of excre-
tion is the kidney, through which it is promptly
cleared unless renal function is appreciably im-
paired. Parenterally injected magnesium has little
effect on renal blood flow and glomerular filtration
[3]. Magnesium not bound to protein is filtered by
the glomeruli, and with normal plasma levels most
of the magnesium is filtered is reabsorbed by the
tubules. Chesley and Tepper [7] clearly demon-
strated, however, that as the plasma magnesium
concentration rises, tubular reabsorption decreases
and renal clearance increases. With plasma levels
typically achieved with the dosage schedule de-
scribed above, the renal clearance of magnesium
approaches the GFR. The creatinine clearance in
the case of eclampsia illustrated in Fig. 1, measured
over 9 hours beginning 0.5 hour after magnesium
sulfate therapy was initiated, averaged 49 mI/mm.
At the same time, the magnesium clearance aver-
aged 30 mI/mm.
(C) Mechanism of action. The effects of the mag-
nesium ion on the central nervous system have been
a source of confusion, although there is no doubt
that magnesium administered parenterally in a suf-
ficient dose will arrest and prevent convulsions in a
variety of conditions, especially eclampsia. In a
dramatic study performed on themselves, Somjen,
Hilmy, and Stephen [8] raised the plasma magne-
sium concentration by slow i.v. infusion of
MgSO47H2O to highs of 15.3 and 14.6 mEq!liter.
Profound paralysis of skeletal muscles was pro-
duced, which spared only the diaphragm, the ad-
ductors of the vocal cords, and some of the facial
muscles. Nonetheless, pain was keenly felt and vi-
sion and hearing were normal.
Elevated concentrations of magnesium decrease
acetylcholine release by motor nerve impulses, re-
duce the sensitivity of the motor end-plate to acetyl-
choline, and decrease the amplitude of the motor
end-plate potential. This peripheral curariform ac-
tion of magnesium in high concentrations, coupled
with the lack of generalized central nervous system
depression, has led to inappropriate conclusions as
to the mechanism of action of magnesium sulfate in
the control of convulsions in eclampsia. Donaldson
[9], for example, considers magnesium sulfate not
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to be an anticonvulsant. Instead, according to him,
the drug simply blocks peripherally the motor re-
sponse to eclampsia-induced cortical dysfunction,
which, in the absence of such a peripheral block,
would be evidenced as a grand mal seizure. Such a
concept fails to take into account that convulsions
commonly are controlled without producing a pe-
ripheral motor block sufficiently intense to impair
deep-tendon reflexes. Moreover, generalized cen-
tral nervous depression cannot be implicated in the
anticonvulsant action of magnesium so adminis-
tered because the woman almost always promptly
stops convulsing and regains consciousness in an
hour or two after magnesium sulfate treatment is
started.
Very important to an understanding of the anti-
convulsant action of magnesium sulfate in eclamp-
sia, evidence was provided by Borges and GUcer
[10] in awake subhuman primates that infused mag-
nesium sulfate suppresses neuronal burst firing and
interictal electroencephalographic spike generation
in neuronal populations rendered epileptic by topi-
cally applied penicillin G. The degree of suppres-
sion increased as the plasma magnesium concentra-
tion increased and decreased as the magnesium
concentration fell. Moreover, the cortical suppres-
sion occurred with plasma magnesium concentra-
tions that were well below those that caused neuro-
muscular blockade.
An antihypertensive action was long attributed to
parenterally administered magnesium not only by
obstetricians caring for women with preeclampsia
and eclampsia but also by pediatricians and inter-
nists who cared for hypertensive individuals, es-
pecially those with acute nephritis. Winkler, Smith,
and Hoff[ll], in 1942, reported their careful studies
of the effect of i.v. administered magnesium on the
blood pressure of adults with and without hyper-
tension. In both groups, the effects were unpredict-
able. in some, during the course of the i.v. infusion,
the pressure fell appreciably, but in others there
was little, if any, change. The fall in blood pressure,
when it did occur, typically lasted only during the
i.v. infusion and for a very brief period thereafter.
Similar transient decreases in blood pressure
have subsequently been recorded in some women
with preeclampsia and eclampsia, as well as in some
nonpregnant hypertensive uremic adults and hyper-
tens lye children with acute glomerulonephritis [3,
4]. During the period of actual i.v. injection, which
produced a high intravascular magnesium concen-
tration, the blood pressure sometimes fell some-
what, only to return to the preinjection range short-
ly thereafter. With i.m. administration, however,
little change in blood pressure was noted, although
magnesium levels effectively controlled con-
vulsions in these three situations.
Magnesium toxicity. Magnesium levels up to at
least 7 mEq/liter are not accompanied by evidence
of toxicity. The first warning of impending toxicity
in the mother is loss of the patellar reflex at plasma
concentrations between 7 to 10 mEq/liter, a phe-
nomenon described first by Winkler et a! [ii] and
demonstrated in Fig. 1. Continued administration of
magnesium is stopped whenever the knee jerk can-
not be elicited lest serious magnesium intoxication
be induced. If loss of the patellar reflex is ignored
and the plasma concentration increases much beyond
10 mEq/liter, impairment of the muscles involved in
respiration can cause dangerous hypoxia [6].
Calcium gluconate, 10 ml of a 10% solution,
steadily injected over 3 mm, is an effective antidote
when respiratory depression has been induced by
hypermagnesemia.
Lipsitz and English [12] attributed respiratory de-
pression and hyporeflexia in a small group of new-
born infants to maternal treatment with i.v. admin-
istered magnesium sulfate. Stone and Pritchard [13]
subsequently reported extensive observations made
at Parkland Memorial Hospital that did not support
the contention of Lipsitz and English that magne-
sium sulfate therapy commonly leads to a depressed
infant. (Indeed, at Parkiand Memorial Hospital dur-
ing the last 23 years, pregnant women have received
parenterally administered magnesium sulfate
amounting to nearly 1,000,000 g, or 1 ton!)
Other anticonvulsants. Diazepam is widely used
to control convulsions from a variety of causes, in-
cluding, at times, those of eclampsia. Our experi-
ence has been limited to those women with eclamp-
sia brought to the Obstetrics Emergency Unit after
receiving a modest dose of only 5 to 10 mg of diaze-
pam elsewhere. In each instance, we expressed
concern over the effects on the infant of larger
doses of diazepam that are often required to control
eclamptic convulsions. Cree, Meyer, and Hailey
[14] have documented in newborns low Apgar
score, apnea several hours after birth, hypotonia,
drowsiness, and impaired metabolic response to
cooling.
Morphine will control convulsions only in doses
that render the woman nearly unconscious. The
generalized central nervous depression produced in
the mother and her fetus is most undesirable.
Antihvpertensive therapy with hydralazine. The
rationale for the dosage schedule used for hydrala-
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zine was to lower the blood pressure of the severely
hypertensive woman to more moderate levels in or-
der to avoid maternal intracranial hemorrhage, yet
without decreasing placental perfusion, which
would further compromise the fetus.
Before delivery, if the diastolic blood pressure
was 110 mm Hg or higher, hydralazine (5 mg) was
injected i.v., and the blood pressure was monitored
every 5 mm. If the diastolic pressure was not low-
ered to the desired level of 90 to 100 mm Hg within
20 mm, 5 to 10 mg more of hydralazine was injected
i.v., and the effect of the dose was again monitored
at 5-mm intervals. The desired effect was achieved
almost always with 5 to 20 mg of hydralazine. The
injection was repeated whenever the diastolic pres-
sure rose to 110 mm Hg or higher [2].
Blood flow through any organ behaves in the fol-
lowing manner:
Blood flow blood pressure
vascular resistance
Whenever arterial blood pressure is reduced, for
blood flow to be maintained in an organ, vascular
resistance in that organ must also be reduced to an
equivalent degree. The unanswered question for
hydralazine, and, for that matter, all antihyper-
tensive agents is: "Does the antihypertensive
agent reduce resistance to blood flow through the
uteroplacental complex sufficiently to compensate
for the decrease in arterial blood pressure?"
That a pharmacologically induced fall in maternal
arterial blood pressure may be deleterious to the fe-
tus is not accepted by everyone. Ferris has argued
that relief of vaso spasm will increase perfusion of
the uterus [15], and he states: "Indeed the previous
belief that an increased blood pressure was neces-
sary for perfusion of vasoconstricted organs is a
perfect example of what Wilfred Trotter termed the
mysterious viability of the false." To support his
argument, Ferris cites no data from human preg-
nancies complicated by hypertension but rather ap-
pears to lean heavily on studies carried out on preg-
nant rabbits rather than some other species, which
would have led to the opposite conclusion. For ex-
ample, Caritis, Morishima, and Stark [16] observed
that in pregnant sheep treated with diazoxide a de-
crease of 20% in maternal blood pressure was ac-
companied by a fall of nearly 40% in uteroplacental
blood flow. The important consideration, of course,
is: "What happens in human gestation?"
In a clinical setting, Michael [17] and Vink,
Moodley, and Philpott [18] have documented omi-
nous fetal heart rate decelerations following the ad-
ministration of diazoxide or dihydralazine to se-
verely hypertensive women whose diastolic blood
pressures fell to less than 90 mm Hg. We have
similarly observed such a response in a woman who
was overtreated inadvertently with hydralazine and
whose blood pressure fell from 190/140 to 110/60
mm Hg. Our interpretation was that the fall in blood
pressure caused a fall in uteroplacental perfusion
and fetal distress in the form of bradycardia. The
fetal heart rate returned to normal as the blood
pressure rose.
For appropriate followup care, it is important to
determine whether the hypertension is totally preg-
nancy-induced or if there is an important com-
ponent of underlying chronic vascular disease that
needs evaluation and long-term treatment. The
problem of serious compromise of placental per-
fusion from doses of hydralazine or other anti-
hypertensive agents sufficient to induce a more in-
tense hypotensive effect is obviated by delivery.
The major problem after delivery is typically that of
controlling severe hypertension for some days as
the pregnancy-induced hypertension abates. When
it has become apparent that the i.v. regimen de-
scribed above had to be used repeated early in the
puerperium, hydralazine was administered i.m.
usually in 10-mg doses at 4- to 6-hour intervals.
Rarely were larger doses needed. As soon as re-
peated blood pressure readings remained near nor-
mal, the hydralazine was stopped. if the hyper-
tension did not recur, serious chronic vascular dis-
ease was most unlikely.
Other antihypertensive agents. In recent years,
enthusiasm has been expressed by some for the use
of diazoxide i.v., especially when the maternal
blood pressure is quite high [13]. Some of the seri-
ous side effects from its use have already been con-
sidered [16, 17]. Because of its marked potency, the
margin for safety may prove to be inadequate for
general use, especially after treatment with another
antihypertensive agent. Moreover, diazoxide induc-
es a number of other potentially dangerous side ef-
fects.
Sodium nitroprusside is contraindicated in preg-
nancy. Lewis et al have demonstrated in pregnant
sheep during the course of inducing a modest fall in
blood pressure with sodium nitroprusside a marked
accumulation of cyanide, especially in the fetus,
and death of the fetus [19].
Diuretics. Oliguria in women with eclampsia or
severe preeclampsia is the consequence of the renal
effects of the disease, or of blood loss, or both.
Therefore, when oliguria was identified, the mother
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was carefully reevaluated with these possibilities in
mind. When the oliguria was the consequence of
blood loss, replacement was promptly instituted. In
the Parkiand regimen, when oliguria was the con-
sequence of the pregnancy-induced hypertension, it
served as an indicator of severe disease, and there-
fore the need for prompt termination of the preg-
nancy. Although a potent diuretic such as furose-
mide would likely have reversed oliguria from ei-
ther cause, it would cure neither. Moreover, the
increased urine flow induced by furosemide would
mask the intensity of both abnormalities.
Edema has been another common indication for
using diuretics, even though the use of potent di-
uretics such as furosemide to try to clear peripheral
edema has not proven to be beneficial. Such thera-
py may, at the same time, reduce blood volume,
and, in turn, further impair uteroplacental and renal
perfusion. For all of these reasons, use of potent
diuretics such as furosemide has been limited at
Parkland Memorial Hospital to the treatment of pul-
monary congestion.
Fluid therapy. In our successfully managed group
of 154 consecutive cases of eclampsia, "routine"
fluid therapy consisted of a balanced salt solution,
such as lactated Ringer's solution, given at the rate
of 60 to 120 mI/hour. Temptation persists to infuse
isoosmotic or hyperosmotic fluids vigorously in an
attempt to overcome the lack of hypervolemia nor-
mally present in pregnancy and the oliguria that
may accompany severe pregnancy-induced hyper-
tension and especially eclampsia. Unfortunately,
such action may cause circulatory overload unless
there is effective relief of the vasospasm, which is
responsible for the decreased capacity of the intra-
vascular compartment. Simultaneous and appropri-
ately integrated manipulation of vasomotor tone and
intravascular contents clearly of benefit to mother
and fetus has not been demonstrated. Circulatory
overload, on one hand, and dangerous levels of
hypotension, on the other, have been documented,
however (Pritchard, unpublished observations).
The woman with a shrunken intravascular com-
partment is less tolerant to blood loss than is the
normal pregnant woman. Blood replacement, there-
fore, must be initiated sooner, and at the same time
more carefully, to prevent both dangerous under-
filling and overfilling. Close monitoring of the cen-
tral venous pressure proved helpful, especially
when oliguria persisted.
In summary, the protocol for the management of
eclampsia and severe preeclampsia used for more
than two decades at Parkiand Memorial Hospital, and
outlined above, has proven highly effective and safe
[2]. Although this protocol has been faulted for em-
piricism, it has not been faulted for achievement.
Management of mild to moderate pregnancy-induced
hypertension
The following protocol for the management of
mild to moderate cases of pregnancy-induced hy-
pertension has been used, as outlined below, in
nearly 1,000 pregnancies during the past decade at
Parkland Memorial Hospital:
All pregnant women whose blood pressure had
risen to 140/90 mm Hg were promptly hospitalized
and, except for cases of eclampsia and fulminant
preeclampsia, were observed closely over the next
several days. Whenever signs and symptoms of se-
vere disease did not ameliorate, management,
which included delivery, was accomplished as de-
scribed on the preceding pages. Otherwise, the
woman and her fetus were cared for with delivery in
the High Risk Pregnancy Unit.
The results achieved with the plan of manage-
ment used on the High Risk Pregnancy Unit have
been remarkable. The pregnancy outcomes for the
first 346 nulliparous women who had become hyper-
tensive in the latter half of pregnancy and were then
cared for on the High Risk Pregnancy Unit were as
follows: As reported by Hauth, Cunningham, and
Whalley [20], in 292 of the 346 women (85%), a good
response was observed; the blood pressures
dropped below 140/90mm Hg within 5 days. Hyper-
tension recurred, however, before labor, but usual-
ly near term, in 47%, and in 42% hypertension re-
curred during labor. Thus, the fall in blood pressure
observed commonly when first admitted represent-
ed amelioration of the vasospasm rather than cure
of the disease.
In 9% of women, the decrease in blood pressure
was less dramatic, but in the absence of other signs
and symptoms of severe preeclampsia, and with the
evidence of favorable fetal growth, the pregnancies
were allowed to continue. In 6% the disease either
remained severe or worsened to become severe
soon after hospitalization, and the pregnancies were
managed as described above.
There were no maternal deaths. There were no
fetal deaths among the 346 pregnancies during the
antepartum period; one fetal death occurred intra-
partum, and two infants died during the neonatal
period. Thus, the perinatal mortality rate was the
remarkably low value of 8.7 per 1,000 live births.
The 5-mm Apgar score was 7 or higher for 92% of
the infants.
The mean birth weight was 2974 g. Only 5 infants
(1.4%) weighed less than 1500 g and 12 (3.5%)
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weighed between 1500 and 2000g. Whereas the ges-
tational age of the fetus when the mother was first
hospitalized was 36 weeks or less for 62% of the
cases, the gestational age at delivery in 91% of the
cases was 37 weeks or more, and therefore the fetus
was essentially mature. The cost of hospitalizing
the mother proved to be remarkably less than the
cost would have been for neonatal intensive care for
a preterm, immature infant.
The 346 women whose pregnancy outcomes are
summarized above, and the several hundred women
similarly cared for since then, were managed as fol-
lows:
Strict bed rest was not enforced. Compared with
their usual outpatient activities, however, the wom-
en were quite sedentary. A general diet without so-
dium restriction or extra protein was provided. The
only medication dispensed was ferrous fumurate,
200 mg, twice each day. Blood pressures were re-
corded 4 times a day while awake. Three times each
week, the women were weighed, and a random
urine specimen was checked for protein content.
Renal function was monitored by measuring the 24-
hour creatinine clearance once a week. For preg-
nancies remote from term, the fetal biparietal diam-
eter and usually the abdominal circumference were
measured to help identify the presence or absence
of retarded fetal growth. Other tests that have been
proposed by some to identify the status of the
health of the fetus were not used. At the outset,
measurements of plasma estriol levels were care-
fully evaluated and subsequently abandoned as
being of little value in the management of preg-
nancy-induced hypertension [21].
The mothers were seen and examined at least
once each day by an obstetric senior resident or fel-
low in maternal-fetal medicine. The overall care
was directly supervised by an experienced obstetri-
cian skilled in the management of pregnancy-in-
duced hypertension.
Deterioration was strongly suggested by the de-
velopment of sudden weight gain, an increase in
blood pressure, the onset of proteinuria that per-
sisted, a rise in plasma creatinine concentration
with a fall in creatinine clearance, the development
of headache or visual disturbances that persisted,
the onset of epigastric or right upper quadrant pain,
the onset of pain over the uterus suggestive of pla-
cental abruption, the failure of the uterus to in-
crease in size, or a decrease in fetal movements.
When it was thought that the condition of the
mother and, in turn, the intrauterine environment
was deteriorating, delivery was accomplished with
the outcomes presented above.
It might be theorized that strict bed rest with the
woman lying on her left side might have improved
renal and uterine perfusion; or that a high-protein
diet would have been beneficial by preventing or
combating hypoproteinemia and hypovolemia; or
that a potent diuretic might have prevented or re-
moved edema and also rid the body of excess so-
dium; or that rigid salt restriction would have the
same effect as a diuretic, or that an antihypertensive
agent with or without a diuretic may have been ben-
eficial. It is emphasized that excellent results have
been obtained for a large number of pregnancies
complicated by pregnancy-induced hypertension
without using any of these modalities of treatment,
which may or may not be beneficial or even safe.
Summary and conclusion. Treatment regimens
for the management of severe preeclampsia-
eclampsia and for mild to moderate pregnancy-in-
duced hypertension have been described. The re-
suits following their use have been evaluated care-
fully and found to be good. Even though the treat-
ment regimens are to a considerable degree empiric,
there are extensive data, rather than theory and
dogma, to justify their clinical application.
Reprint requests to Dr. J. A. Pritchard, University of Texas
Southwestern Medical School, Dallas, Texas 75235 USA
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